A U.S. District Court judge ruled in favor of New York-based Pfizer (NYSE: [[ticker:PFE]]) in a patent-infringement case brought by Israel’s generic drug giant Teva (NASDAQ: [[ticker:TEVA]]) over impotence blockbuster sildenafil (Viagra), according to a press release. Teva had been trying to invalidate Pfizer’s patent so it could market a generic version of the drug, but the ruling upholds Pfizer’s patent protection until 2019. Sildenafil is one of Pfizer’s biggest hits, bringing in $1.9 billion in sales in 2010.
Author: Arlene Weintraub
Arlene is an award-winning journalist specializing in life sciences and technology. She was previously a senior health writer based out of the New York City headquarters of BusinessWeek, where she wrote hundreds of articles that explored both the science and business of health. Her freelance pieces have been published in USA Today, US News & World Report, Technology Review, and other media outlets. Arlene has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the anti-aging industry, Selling the Fountain of Youth, was published by Basic Books in September 2010.
View all posts by Arlene Weintraub
